scholarly journals Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984-2005

BMJ ◽  
2009 ◽  
Vol 338 (jan26 2) ◽  
pp. b36-b36 ◽  
Author(s):  
T. Briffa ◽  
S Hickling ◽  
M Knuiman ◽  
M Hobbs ◽  
J Hung ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Population Based ◽  
Evidence Based ◽  
Term Survival ◽  
Long Term Survival ◽  
Evidence Based Treatment

Age-related trends in short- and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975–1995)

1998 ◽  
Vol 82 (11) ◽  
pp. 1311-1317 ◽  
Author(s):  
Robert J Goldberg ◽  
Danny McCormick ◽  
Jerry H Gurwitz ◽  
Jorge Yarzebski ◽  
Darleen Lessard ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Population Based ◽  
Term Survival ◽  
Long Term Survival ◽  
Age Related ◽  
Short And Long Term

scholarly journals Influence of risk factors on long-term survival following acute myocardial infarction: A follow-up study in central japan

1989 ◽  
Vol 12 (9) ◽  
pp. 491-499 ◽  
Author(s):  
N. Enomoto ◽  
K. Yamauchi ◽  
H. Hayashi ◽  
H. Saito ◽  
N. Hamajima ◽  
...  
Keyword(s):  
Risk Factors ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Central Japan ◽  
Term Survival ◽  
Long Term Survival ◽  
Follow Up Study

Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study

Heart ◽  
2013 ◽  
Vol 99 (18) ◽  
pp. 1353-1358 ◽  
Author(s):  
Anthony S Gunnell ◽  
Kristjana Einarsdóttir ◽  
Frank Sanfilippo ◽  
Danny Liew ◽  
C D'Arcy J Holman ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Population Based ◽  
Combination Therapies ◽  
Term Survival ◽  
Population Based Study ◽  
Long Term Survival

scholarly journals Long-Term Survival after Acute Myocardial Infarction in Lithuania During Transitional Period (1996–2015): Data from Population-Based Kaunas Ischemic Heart Disease Register

Medicina ◽  
2019 ◽  
Vol 55 (7) ◽  
pp. 357
Author(s):  
Radisauskas ◽  
Kirvaitiene ◽  
Bernotiene ◽  
Virviciutė ◽  
Ustinaviciene ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Population Based ◽  
Term Survival ◽  
Long Term Survival ◽  
Kaplan Meier ◽  
All Cause Mortality

Background and Objective: There is a lack of reliable epidemiological data on the long-term survival after acute myocardial infarction (AMI) in the Lithuanian population. The aim of the study was to evaluate the long-term (36 months) survival after AMI among persons aged 25–64 years, who had experienced AMI in four time-periods 1996, 2003–2004, 2008, and 2012. Material and Methods: The source of the data was Kaunas population-based Ischemic heart disease (IHD) register. Long-term survival after AMI (36 months) was evaluated using the Kaplan–Meier method. The survival curves significantly differed when p < 0.05. Hazard ratio for all-cause mortality and their 95% CIs, adjusted for baseline characteristics, were estimated with the Cox proportional hazards regression model. Results: The analysis of data on 36 months long-term survival among Kaunas population by sex and age groups showed that the survival rates among men and women were 83.4% and 87.6%, respectively (p < 0.05) and among 25–54 years-old and 55–64 years-old persons, 89.2% and 81.7%, respectively (p < 0.05). The rates of long-term survival of post-AMI Kaunas population were better in past periods than in first period. According to the data of the Kaplan-Meier survival analysis, long-term survival of 25 to 64-year-old post-AMI Kaunas population was without significantly difference in 1996, 2003–2004, 2008 and 2012 (Log-rank = 6.736, p = 0.081). The adjusted risk of all-cause mortality during 36 months among men and 25 to 54-year-old patients was on the average by 35% and 60% lower in 2012 than in 1996, respectively. Conclusion: It was found that 36 months survival post MI among women and younger (25–54 years) persons was significant better compared to men and older (55–64 years) persons. Long-term survival among 55 to 64-year-old post-AMI Kaunas population had a tendency to decrease during last period, while among 25–54 years old persons long-term survival was without significant changes. The results highlight the fact that AMI survivors, especially in youngest age, remain a high-risk group and reinforce the importance of primary and secondary prevention for the improvement of long-term prognosis of AMI patients.

scholarly journals Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure

Heart ◽  
2021 ◽  
Vol 107 (5) ◽  
pp. 389-395
Author(s):  
Jianhua Wu ◽  
Alistair S Hall ◽  
Chris P Gale
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Life Expectancy ◽  
Survival Benefit ◽  
Ace Inhibition ◽  
Survival Times ◽  
Term Survival ◽  
Long Term Survival

AimsACE inhibition reduces mortality and morbidity in patients with heart failure after acute myocardial infarction (AMI). However, there are limited randomised data about the long-term survival benefits of ACE inhibition in this population.MethodsIn 1993, the Acute Infarction Ramipril Efficacy (AIRE) study randomly allocated patients with AMI and clinical heart failure to ramipril or placebo. The duration of masked trial therapy in the UK cohort (603 patients, mean age=64.7 years, 455 male patients) was 12.4 and 13.4 months for ramipril (n=302) and placebo (n=301), respectively. We estimated life expectancy and extensions of life (difference in median survival times) according to duration of follow-up (range 0–29.6 years).ResultsBy 9 April 2019, death from all causes occurred in 266 (88.4%) patients in placebo arm and 275 (91.1%) patients in ramipril arm. The extension of life between ramipril and placebo groups was 14.5 months (95% CI 13.2 to 15.8). Ramipril increased life expectancy more for patients with than without diabetes (life expectancy difference 32.1 vs 5.0 months), previous AMI (20.1 vs 4.9 months), previous heart failure (19.5 vs 4.9 months), hypertension (16.6 vs 8.3 months), angina (16.2 vs 5.0 months) and age >65 years (11.3 vs 5.7 months). Given potential treatment switching, the true absolute treatment effect could be underestimated by 28%.ConclusionFor patients with clinically defined heart failure following AMI, ramipril results in a sustained survival benefit, and is associated with an extension of life of up to 14.5 months for, on average, 13 months treatment duration.

Sign in / Sign up

Export Citation Format

Share Document